Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Maria Laura Acosta-Felquer"'
Publikováno v:
Current Opinion in Rheumatology. 30:87-93
Purpose of review The review gives an updated overview of some of the new concepts in the management of psoriatic arthritis (PsA): early diagnosis, remission as an objective, treat-to-target, and treatment guidelines. Recent findings Early diagnosis,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9032f98a9a2f4d31f82bbaa8fa50232
https://doi.org/10.1097/bor.0000000000000468
https://doi.org/10.1097/bor.0000000000000468
Autor:
Maria Laura Acosta-Felquer, Santiago Ruta, Leandro Ferreyra-Garrot, Ricardo Galimberti, Enrique R. Soriano, Josefina Marin, Ricardo García-Mónaco, Javier Rosa, María Laura Galimberti
Publikováno v:
Seminars in Arthritis and Rheumatism. 47:338-342
It has been shown that nail involvement in psoriasis is associated with systemic enthesopathy. Our objective was to evaluate the association of nail involvement and enthesopathy at distal interphalangeal joint (DIP) level in psoriasis (PsO) and psori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f540b4cc4ccf118591c8437602eac90
https://doi.org/10.1016/j.semarthrit.2017.05.002
https://doi.org/10.1016/j.semarthrit.2017.05.002
Autor:
Philip J. Mease, Denis O'Sullivan, Sergio Toloza, Enrique R. Soriano, Andrew Parkinson, Wolf-Henning Boehncke, Arthur Kavanaugh, Alexis Ogdie, Alice B. Gottlieb, M. Elaine Husni, Thorvardur Jon Love, Sergio Schwartzman, Peter Nash, Luis R. Espinoza, Wilson Bautista-Molano, Laura C. Coates, Dafna D. Gladman, William Tuong, April W. Armstrong, Philip S. Helliwell, Alberto Cauli, Maria Laura Acosta-Felquer, Cheryl F. Rosen, Christopher T. Ritchlin, Oliver FitzGerald, Neil McHugh, Ana Maria Orbai, Evan L. Siegel, Willemina Campbell, Ennio Lubrano
Publikováno v:
Arthritis & Rheumatology.
Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA). Methods GRAPPA rheumatologist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edc17f9b173029e4f752c23f1bae25bd
https://doi.org/10.1002/art.39573
https://doi.org/10.1002/art.39573
Autor:
Laura C, Coates, Arthur, Kavanaugh, Philip J, Mease, Enrique R, Soriano, Maria, Laura Acosta-Felquer, April W, Armstrong, Wilson, Bautista-Molano, Wolf-Henning, Boehncke, Willemina, Campbell, Alberto, Cauli, Luis R, Espinoza, Oliver, FitzGerald, Dafna D, Gladman, Alice, Gottlieb, Philip S, Helliwell, M Elaine, Husni, Thorvardur J, Love, Ennio, Lubrano, Neil, McHugh, Peter, Nash, Alexis, Ogdie, Ana-Maria, Orbai, Andrew, Parkinson, Denis, O'Sullivan, Cheryl F, Rosen, Sergio, Schwartzman, Evan L, Siegel, Sergio, Toloza, William, Tuong, Christopher T, Ritchlin
To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA).GRAPPA rheumatologists, dermatologists,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1976bf579f443040b5b6616b67b9a346
http://hdl.handle.net/11695/52395
http://hdl.handle.net/11695/52395
Publikováno v:
Clinical and experimental rheumatology. 33(5 Suppl 93)
Peripheral joint involvement is a common, potentially debilitating feature of psoriatic arthritis (PsA). Joint involvement is commonly symmetrical and polyarticular similar to rheumatoid arthritis (RA) but it can also be oligoarticular, asymmetrical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8f1ad8fde876261bb0dc4093549198f9
https://pubmed.ncbi.nlm.nih.gov/26471860
https://pubmed.ncbi.nlm.nih.gov/26471860
Publikováno v:
Best practiceresearch. Clinical rheumatology. 28(5)
This manuscript focuses on the pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis – including ankylosing spondylitis – using traditional biologic and non-biologic disease-modifying antirheumatic drugs. Early treatment of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76a12f36119f6603e9420b5055919403
https://pubmed.ncbi.nlm.nih.gov/25488785
https://pubmed.ncbi.nlm.nih.gov/25488785
Autor:
Maria Laura Acosta Felquer, Laura C. Coates, Enrique R. Soriano, Roberto Ranza, Luis R. Espinoza, Philip S. Helliwell, Oliver FitzGerald, Neil McHugh, Euthalia Roussou, Philip J. Mease
Publikováno v:
Acosta Felquer, M L, Coates, L C, Soriano, E R, Ranza, R, Espinoza, L R, Helliwell, P S, FitzGerald, O, McHugh, N, Roussou, E & Mease, P J 2014, ' Drug therapies for peripheral joint disease in psoriatic arthritis : a systematic review ', The Journal of Rheumatology, vol. 41, no. 11, pp. 2277-2285 . https://doi.org/10.3899/jrheum.140876
Traditional drug treatments for psoriatic arthritis (PsA) include nonsteroidal antiinflammatory agents (NSAID) and disease modifying antirheumatic drugs (DMARD), although the evidence base for their effectiveness is not well established. This review
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82daa3bafb61abca35e5e53536f87e99
https://pubmed.ncbi.nlm.nih.gov/25362711
https://pubmed.ncbi.nlm.nih.gov/25362711
Publikováno v:
Open Access Rheumatology : Research and Reviews
Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of psoriatic arthritis (PsA) in Europe, the USA, and Latin American countries. CZP neutralizes TNF-α at its soluble and membrane p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30781832b193cc5dcc49233f66917a0e
https://doi.org/10.2147/oarrr.s56837
https://doi.org/10.2147/oarrr.s56837